The ICRH and CTS established the Distinguished Lecture in Respiratory Sciences Award in 2006 to honour scholars in the respiratory field. Nominations are solicited from the respiratory research community and assessed against the following criteria:

  • impact of the nominee’s research on respiratory sciences in Canada and the extent to which the nominee has contributed significantly to the advancement of respiratory sciences in Canada over the last ten years;
  • relevance/application/impact of nominee’s research to a clinical setting; and
  • demonstrated strength and reputation of the nominee in the field of respiratory sciences in Canada.

It is with great pleasure that CIHR-ICRH and CTS announce that the 2019 Distinguished Lecture in Respiratory Sciences has been awarded to Dr. Dick Menzies from McGill University. Dr. Menzies has been involved in TB research for almost 30 years and in shaping diagnosis, treatment, and prevention policy and practice at the provincial, national, and international level. He is the Editor of the 7th edition Canadian Tuberculosis Standards and will present on the topic of ‘Treatment of Latent TB Infection – safety first. Time to move on from INH’.

Session Description
This lecture will review the pathogenesis of TB and the rationale for treatment of latent TB. Diagnosis and management, including the concept of cascade of care in latent TB will be discussed. The treatment of latent TB, including the current standard of INH for six – nine months, three to four months INH & Rifampin and three months INH & Rifapentine will be reviewed. Finally, two recent trials of four months Rifampin will be discussed. The lecture will conclude with a comparison of the different treatment options and the rationale for moving on from INH to some Rifamycin-based treatments.

Learning Objectives
At the end of this presentation, attendees will be able to:

  • understand the rationale for treatment of latent TB;
  • comprehend the different treatment options for latent TB and their advantages and disadvantages; and
  • recognize why we need to stop using INH as our standard treatment and move on to a rifampin or rifapentine–based regimen.